Senores Pharmaceuticals has announced the availability of the audio recording from its Earnings Conference Call held on Monday, July 27, 2026, pertaining to the company's unaudited financial results for the quarter ended June 30, 2026. The call was conducted with several analysts, institutional investors, funds, and other investors, in accordance with Regulations 30 and 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Earnings Call Details

The following key details pertain to the Earnings Conference Call conducted by Senores Pharmaceuticals:

Regulatory Compliance

The disclosure was made in compliance with SEBI's listing regulations, and the company has confirmed that no Unpublished Price Sensitive Information (UPSI) was shared or discussed during the Earnings Conference Call. The filing was signed by Deval Rajnikant Shah, Whole Time Director & CFO (DIN: 00332722), on July 27, 2026.

Access to Recording

Investors and other stakeholders can access the audio recording of the Earnings Conference Call through the company's investor relations page at https://senorespharma.com/investor-meet/ . The recording has been made available as part of the company's ongoing commitment to transparency and regulatory compliance under applicable SEBI listing norms.

Senores Pharmaceuticals reported a robust performance in Q1, with consolidated net profit climbing to 307M rupees compared to 197M rupees in the same quarter of the previous year, reflecting strong year-on-year growth across key financial metrics.

Revenue and Profitability Performance

The company's top line showed meaningful improvement, with quarterly revenue rising to 1.8B rupees from 1.4B rupees year-on-year. The growth in revenue was accompanied by a significant expansion in operating profitability, underscoring improved operational efficiency during the period.

The following table summarises the key financial metrics for Q1 on a year-on-year basis:

EBITDA and Margin Expansion

Senores Pharmaceuticals reported EBITDA of 538M rupees for Q1, nearly doubling from 285M rupees recorded in the year-ago period. The EBITDA margin expanded sharply to 29.80% from 21.48% year-on-year, indicating a notable improvement in the company's cost structure and operating leverage during the quarter.

Key Highlights

• Net Profit rose to 307M rupees from 197M rupees (YoY)
• EBITDA increased to 538M rupees from 285M rupees (YoY)
• EBITDA Margin expanded to 29.80% from 21.48% (YoY)
• Revenue grew to 1.8B rupees from 1.4B rupees (YoY)

The Q1 results reflect broad-based improvement across revenue, operating profit, and margins for Senores Pharmaceuticals on a year-on-year basis, with EBITDA margin crossing the 29% mark during the reported quarter.